Johnson & Johnson (NYSE:JNJ) Shares Sold by Arnhold LLC

Arnhold LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 8.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,150 shares of the company’s stock after selling 1,085 shares during the quarter. Arnhold LLC’s holdings in Johnson & Johnson were worth $1,764,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Christopher J. Hasenberg Inc acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $31,000. Keener Financial Planning LLC bought a new position in Johnson & Johnson during the 4th quarter worth $40,000. WFA Asset Management Corp lifted its stake in Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $44,000. Finally, Disciplined Equity Management Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $45,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on JNJ shares. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, July 1st. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.88 on Tuesday, reaching $150.12. 1,345,227 shares of the company traded hands, compared to its average volume of 7,228,327. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The stock has a market capitalization of $361.29 billion, a PE ratio of 9.37, a P/E/G ratio of 2.52 and a beta of 0.52. The company’s 50 day moving average is $147.95 and its 200-day moving average is $153.41. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the company posted $2.68 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.